Streck adds Accellix platform to CD-Chex Plus RUO control
November 2025—Streck added the Accellix automated cell phenotyping platform to its CD-Chex Plus (RUO) control.
Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Qiagen launches QIAstat-Dx Rise
November 2025—Qiagen launched QIAstat Dx Rise, an FDA-cleared automated syndromic testing system for hospitals and laboratories.
CytoCell KMT2A FISH probe kit granted de novo classification
November 2025—FDA granted de novo classification for OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for Syndax’s menin inhibitor, Revuforj.
Molecular Designs submits respiratory panel for 510(k) clearance
November 2025—Molecular Designs submitted a 510(k) premarket notification to the FDA for its SimplicityDx Respiratory panel, designed to detect SARS-CoV-2, influenza A, influenza B, and RSV.
Quest launches advanced PGx test service
November 2025—Quest Diagnostics launched a pharmacogenomic laboratory test service to help providers understand a patient’s genetic response to drug therapies.
Guardant, PathGroup partner to expand access to Shield test
November 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test for colorectal cancer screening.
Data presented at ACEP25 show the utility of MeMed BV
November 2025—Presentations at the American College of Emergency Physicians Scientific Assembly 2025 highlighted MeMed BV’s effectiveness in distinguishing between bacterial and viral infections.
Tosoh gets clearance for next-gen GR01 HbA1c analyzer
November 2025—Tosoh Bioscience received FDA clearance for its HLC 723-GR01 analyzer, which uses proprietary technology to deliver A1c results in 50 seconds and detect common hemoglobin variants.
Abbott gets expanded approval for HPV assay
November 2025—FDA approves Abbott’s Alinity m HR HPV assay for self-collected vaginal samples in clinical settings.
Quickvue Influenza + SARS test available for professional use
November 2025—QuidelOrtho’s Quickvue Influenza + SARS test, a CLIA-waived immunoassay, is now available for professional use.